- Home
- CYH vs PHAR Comparison
CYH vs PHAR Comparison
Compare CYH & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- PHAR
- Stock Information
- Founded
- CYH 1985
- PHAR 1988
- Country
- CYH United States
- PHAR Netherlands
- Employees
- CYH N/A
- PHAR N/A
- Industry
- CYH Hospital/Nursing Management
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- PHAR Health Care
- Exchange
- CYH Nasdaq
- PHAR Nasdaq
- Market Cap
- CYH 482.7M
- PHAR 731.1M
- IPO Year
- CYH 1991
- PHAR N/A
- Fundamental
- Price
- CYH $3.59
- PHAR $10.00
- Analyst Decision
- CYH Hold
- PHAR Strong Buy
- Analyst Count
- CYH 8
- PHAR 3
- Target Price
- CYH $4.27
- PHAR $30.00
- AVG Volume (30 Days)
- CYH 2.2M
- PHAR 3.6K
- Earning Date
- CYH 07-23-2025
- PHAR 07-31-2025
- Dividend Yield
- CYH N/A
- PHAR N/A
- EPS Growth
- CYH N/A
- PHAR N/A
- EPS
- CYH N/A
- PHAR N/A
- Revenue
- CYH $12,653,000,000.00
- PHAR $320,708,000.00
- Revenue This Year
- CYH N/A
- PHAR $13.31
- Revenue Next Year
- CYH $3.49
- PHAR $7.68
- P/E Ratio
- CYH N/A
- PHAR N/A
- Revenue Growth
- CYH 1.05
- PHAR 24.13
- 52 Week Low
- CYH $2.24
- PHAR $6.65
- 52 Week High
- CYH $6.29
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- CYH 56.80
- PHAR 43.61
- Support Level
- CYH $3.44
- PHAR $9.99
- Resistance Level
- CYH $3.64
- PHAR $10.59
- Average True Range (ATR)
- CYH 0.17
- PHAR 0.35
- MACD
- CYH 0.03
- PHAR -0.14
- Stochastic Oscillator
- CYH 80.95
- PHAR 7.45
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.